Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score

BACKGROUND: Cytokine release syndrome (CRS), characterized by overproduction of proinflammatory cytokines in the course of severe coronavirus disease 2019 (COVID-19), has been suggested as the major cause of mortality. Tocilizumab, a recombinant humanized monoclonal antibody against human IL-6 recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Eşkazan, Ahmet Emre, Balkan, İlker İnanç, Demirbaş, Kaan Can, Ar, Muhlis Cem, Karaali, Rıdvan, Sekibağ, Yonca, Mulamahmutoğlu, Sait, Yartaş Dumanlı, Güleren, Çakmak, Fatih, Özgür Yurttaş, Nurgül, Kurt, Furkan, Aladağ Kurt, Seda, Kuşkucu, Mert, Ürkmez, Seval, Börekçi, Şermin, Saribal, Devrim, Mete, Bilgül, Bavunoğlu, Işıl, Dikmen, Yalım, Aygün, Gökhan, Midilli, Kenan, Tabak, Fehmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114762/
https://www.ncbi.nlm.nih.gov/pubmed/34120824
http://dx.doi.org/10.1016/j.jiac.2021.05.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114762/
https://www.ncbi.nlm.nih.gov/pubmed/34120824
http://dx.doi.org/10.1016/j.jiac.2021.05.007

Ejemplares similares